Evidence map›Paper›PMID 21135371›Full record

ReviewCirculation2010

Genetics and clinical destiny: improving care in hypertrophic cardiomyopathy.

Carolyn Y Ho

Abstract readReview
In one paragraph

Review in Circulation, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Catheter ablation of atrial fibrillation in patients with and without hypertrophic cardiomyopathy: systematic review and meta-analysis.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2023
    Pooled it
  2. Clinical outcomes associated with sarcomere mutations in hypertrophic cardiomyopathy: a meta-analysis on 7675 individuals.Clinical research in cardiology : official journal of the German Cardiac Society · 2018
    Pooled it
  3. Article
  4. Observational
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Genetic Testing in Patients with Hypertrophic Cardiomyopathy.International journal of molecular sciences · 2021
    Review
  15. Review
  16. Hypertrophic cardiomyopathy.International journal of cardiology. Heart & vasculature · 2020
    Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Carolyn Y HoCardiovascular Genetics Center, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. cho@partners.org

Funding

Using Genetics for Early Phenotyping & Prevention of Hypertrophic CardiomyopathyP20HL101408 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI HO, CAROLYN Y, SEIDMAN, CHRISTINE E · 2010 to 2011
$1.5M
Diagnostic and Treatment Strategies for Preclinical HCMK23HL078901 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI HO, CAROLYN Y · 2005 to 2009
$795k
NHLBI NIH HHS K23 HL078901NHLBI NIH HHS P20 HL101408
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Cardiomyopathy, HypertrophicGenetic Predisposition to DiseaseGenetic TestingHumansPatient CareTreatment Outcome

Identifiers

PMID21135371
PMCPMC3100192

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.